© 2016 In the abovementioned article, we have erroneously listed the concentrations of cyclodextrins in the description of Fig. 6 (bottom of the graph and figure legend). The correct concentrations were 0.1, 1 and 10 mM. The corresponding text referring to these results in section 3.3. also has erroneous concentrations. We would like to correct these concentrations as shown below. These corrections do not change the conclusions of the paper. Legend for Fig. 6. Comparative effects of hydroxyalkylated β-CDs on the cholesterol-solubilizing ability in an aqueous buffer. HEBCD, HPBCD, and HBBCD at 0.1–10 mM were incubated with cholesterol in DMEM/F-12 medium, and then cholesterol levels were measured using the Determiner L FC kit. Each bar represents the mean ± S.E.M., (n = 3). #P  <  0.05 and ##P  <  0.01 compared with HPBCD treated groups at different concentrations. 3.3. Influence of the difference in hydroxyalkyl groups of β-CDs on the preventive effects against abnormal intracellular cholesterol and lysosomal volume in Npc1 null cells. The differences in hydroxyalkyl groups appeared to affect the attenuating effects of β-CDs on the dysfunctional cholesterol sequestration and lysosomal volume in Npc1 null cells. The D.S. values of HEBCD and HBBCD used in this study were 12.8 and 4.4, respectively. As shown in Fig. 5, HPBCD and HBBCD attenuated the increases in FC level and fluorescence intensity of LysoTracker® and the decrease in EC levels observed in Npc1 null control cells. HEBCD tended to attenuate the abnormalities observed in Npc1 null cells, and there was no statistical difference in the changes of FC and EC levels compared with Npc1 null control cells. However, the increase in LysoTracker® fluorescence intensity was significantly attenuated by 1 mM of HEBCD treatment. In addition, no significant difference was observed between HPBCD and HBBCD, although significant differences were observed between HPBCD and HEBCD groups (Fig. 5). As shown in Fig. 6, HPBCD solubilized FC in the culture medium in a dose-dependent manner. HPBCD at 1 and 10 mM was able to solubilize approximately 1 and 20 μM FC, respectively. HBBCD showed a potent cholesterol-solubilizing effect that was approximately 5 times higher than that of HPBCD. On the other hand, the cholesterol-solubilizing effect of HEBCD was weaker than that of HPBCD and HBBCD. The effect of 10 mM HEBCD was equal to that of 1 mM HPBCD.